New strategies in chronic myeloid leukemia.
Most patients with chronic myeloid leukemia (CML) achieve clinically relevant hematologic and cytogenetic responses to imatinib. Patients who show resistance to imatinib need new therapeutic options. A range of options are being developed to treat imatinib-resistant patients who have CML. Promising results of early-phase clinical trials have been reported for new tyrosine kinase inhibitors, farnesyl transferase inhibitors, decitabine, homoharringtonine, and vaccines. Further clinical trials are needed to characterize the efficacy and safety profile of these new agents and to determine which agents improve the long-term prognosis for patients with CML who have shown resistance to imatinib.
Kantarjian
Hagop M
HM
Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
Cortes
Jorge
J
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001549:Benzamides; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077209:Decitabine; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D005260:Female; D006248:Harringtonines / Q000009:adverse effects / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000201:enzymology / Q000628:therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
D020533:Angiogenesis Inhibitors; D001549:Benzamides; D019496:Cancer Vaccines; D006248:Harringtonines; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000077863:Homoharringtonine; D000077209:Decitabine; D000068877:Imatinib Mesylate; D013186:Farnesyl-Diphosphate Farnesyltransferase; D011505:Protein-Tyrosine Kinases; D001374:Azacitidine